LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akcijų sąrašas・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

15.44 2.86

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.02

Max

15.49

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-130B -25B
Pardavimai	-99B 1.1T
P/E Sektoriaus vid.	39.974 49.888
Pelnas, tenkantis vienai akcijai	0.21
Dividendų pajamingumas	4.35
Pelno marža	-2.222
Darbuotojai	47,455
EBITDA	-242B 214B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+39.72% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	4.35% 2.38%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-3.7B 48B
Ankstesnė atidarymo kaina	12.58
Ankstesnė uždarymo kaina	15.44

Naujienos nuotaikos

By Acuity

100%

325 / 344 reitingas Healthcare

Takeda Pharmaceutical Co Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-13 08:59; UTC

Uždarbis

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

2026-01-29 07:11; UTC

Uždarbis

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

2025-12-19 03:32; UTC

Pagrindinės rinkos jėgos

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

2025-10-30 09:39; UTC

Uždarbis

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

2025-10-30 07:32; UTC

Uždarbis

Takeda Posts Quarterly Net Loss, Cuts Guidance

2026-05-13 06:57; UTC

Uždarbis

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

2026-05-13 06:54; UTC

Uždarbis

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

2026-05-13 06:44; UTC

Uždarbis

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

2026-05-13 06:38; UTC

Uždarbis

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

2026-05-13 06:31; UTC

Uždarbis

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

2026-05-13 06:31; UTC

Uždarbis

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

2026-05-13 06:31; UTC

Uždarbis

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

2026-05-13 06:31; UTC

Uždarbis

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

2026-05-13 06:31; UTC

Uždarbis

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

2026-05-13 06:31; UTC

Uždarbis

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

2026-01-29 06:53; UTC

Uždarbis

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

2026-01-29 06:36; UTC

Uždarbis

Takeda Raises FY Revenue, Net-Profit Views

2026-01-29 06:34; UTC

Uždarbis

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

2026-01-29 06:33; UTC

Uždarbis

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

2026-01-29 06:32; UTC

Uždarbis

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

2026-01-29 06:30; UTC

Uždarbis

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

2025-10-30 07:10; UTC

Uždarbis

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

2025-10-30 06:50; UTC

Uždarbis

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

2025-10-30 06:49; UTC

Uždarbis

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

2025-10-30 06:48; UTC

Uždarbis

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Akcijų palyginimas

Kainos pokytis

Takeda Pharmaceutical Co Ltd ADR Prognozė

Kainos tikslas

By TipRanks

39.72% į viršų

12 mėnesių prognozė

Vidutinis 21 USD 39.72%

Aukščiausias 21 USD

Žemiausias 21 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Takeda Pharmaceutical Co Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Takeda Pharmaceutical Co Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.